💊 3rd-Gen Cephalosporin

Cefpodoxime for Dogs Dosage Calculator

Evidence-based cefpodoxime proxetil (Simplicef) dosing for dogs — covering all FDA-approved indications, treatment duration protocols, culture/sensitivity interpretation, and tablet selection across the full weight range.

⚠️

Prescription antibiotic — complete the full course. Do not discontinue early even if signs resolve — incomplete courses promote antibiotic resistance. Avoid in dogs with known cephalosporin or penicillin hypersensitivity. Use with food to improve absorption and reduce GI effects.

What Is Cefpodoxime (Simplicef)?

Cefpodoxime proxetil (Simplicef) is an orally-administered, third-generation cephalosporin antibiotic that is FDA-approved for the treatment of skin infections (pyoderma) and urinary tract infections in dogs. It is a prodrug — the proxetil ester is hydrolysed by intestinal esterases after absorption, releasing active cefpodoxime. Third-generation cephalosporins have an expanded spectrum against gram-negative bacteria compared to first- and second-generation agents, while retaining good gram-positive activity.

Cefpodoxime exerts bactericidal activity by binding penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting transpeptidase and blocking peptidoglycan cross-linking during cell wall synthesis. It is time-dependent in its killing — efficacy depends on the proportion of time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen.

Spectrum of Activity

  • Gram-positive: Staphylococcus pseudintermedius (including some MRSP strains are NOT sensitive), Streptococcus canis, Enterococcus spp. (variable)
  • Gram-negative: E. coli, Proteus mirabilis, Klebsiella pneumoniae, Pasteurella multocida
  • NOT effective against: Pseudomonas aeruginosa, Enterococcus faecium, anaerobes (limited), MRSA, MRSP
  • Beta-lactamase: Stable against many beta-lactamases; NOT against extended-spectrum beta-lactamases (ESBLs)

Pharmacokinetics in Dogs

  • Oral bioavailability: ~63% (increases with food — give with meals)
  • Time to peak plasma (Tmax): ~2 hours post-dose
  • Half-life (dogs): ~5.6 hours
  • Volume of distribution: Achieves excellent skin and urinary tract concentrations
  • Elimination: ~80% renal — dose adjustment may be needed in severe renal impairment
  • Protein binding: Low (~22–23%) — high free drug fraction

FDA-Approved Indications & Durations

  • Superficial pyoderma (skin infections): 5–10 mg/kg q24h × 5–7 days
  • Deep pyoderma / skin fold dermatitis: 5–10 mg/kg q24h × 21–28 days (or until 7 days after resolution)
  • Urinary tract infection (uncomplicated): 5–10 mg/kg q24h × 7 days
  • UTI (complicated / recurrent): 5–10 mg/kg q24h × 4–6 weeks based on culture sensitivity
  • Wound infections / secondary bacterial infections: 5–10 mg/kg q24h × 7–14 days

Available Tablets

  • 100 mg film-coated tablets (Simplicef)
  • 200 mg film-coated tablets (Simplicef)

How to Use This Calculator

  1. Enter your dog’s body weight in kg or lbs — use current accurate weight
  2. Select the clinical indication — this determines dose range and recommended treatment duration
  3. Choose the tablet strength available (100 mg or 200 mg)
  4. Enter the prescription start date to generate a complete treatment schedule
  5. Check if culture & sensitivity results are available — always use C&S to confirm susceptibility in recurrent or complicated infections
  6. Click Calculate for dose, tablets per day, total tablets for course, and dated schedule

🧮 Cefpodoxime Dose Calculator

Generates full course schedule

Cefpodoxime Dosing Result

Daily dose

Culture & Sensitivity Guidance

For recurrent or complicated infections, always submit a culture and sensitivity (C&S) sample before starting antibiotics:

Infection Type Sample When to C&S
Recurrent UTI (>2 episodes/year) Cystocentesis urine Before every antibiotic course
Deep pyoderma Tissue biopsy or pustule contents Before first and any repeated course
Suspected MRSP Pustule contents / nasal swab Before starting any antibiotic
Non-responsive skin infection (>3 weeks) Skin punch biopsy Immediately
First-time simple UTI Cystocentesis urine Optional — empirical treatment acceptable

Frequently Asked Questions

Cefpodoxime achieves once-daily dosing in dogs due to its pharmacokinetic profile in the canine species — specifically its half-life of approximately 5.6 hours combined with a post-antibiotic effect and the time-above-MIC parameters for target pathogens. The 10 mg/kg dose maintains free drug concentrations above the MIC for S. pseudintermedius and common UTI pathogens for sufficient time with a 24-hour interval. Dogs metabolise cefpodoxime differently from humans (who require twice-daily dosing), which is why the veterinary product is dosed q24h rather than q12h.

Use with caution. Cephalosporins and penicillins share a beta-lactam ring structure, and cross-reactivity exists in a minority of patients. The reported cross-reactivity rate between penicillins and cephalosporins is approximately 1–4% in people; veterinary-specific data is limited. If a dog had a mild penicillin reaction (GI upset), cephalosporins are generally considered safe. If a dog experienced a severe immediate hypersensitivity reaction (anaphylaxis, urticaria) to penicillin, cephalosporins should be used with extreme caution or avoided — consult your veterinarian.

Both are third-generation cephalosporins for dogs, but with very different delivery systems. Simplicef (cefpodoxime proxetil) is an oral tablet given once daily — flexible dosing, owner-administered. Convenia (cefovecin sodium) is a long-acting SC injection given by a veterinarian that provides therapeutic drug levels for up to 14 days from a single injection. Convenia is ideal for dogs that are difficult to medicate orally. The antibiotic spectra are similar, though there are pharmacokinetic differences. Simplicef allows more control over dose adjustments and early discontinuation if adverse effects occur.

Cefpodoxime is not FDA-approved for otitis externa and is not a first-line choice for this condition. Otitis externa is typically treated with topical antibiotic preparations (enrofloxacin, gentamicin, silver sulfadiazine) combined with antifungal and anti-inflammatory agents in the ear canal. Systemic antibiotics for otitis are indicated only for concurrent otitis media/interna or severe deep-tissue involvement. If cefpodoxime is used off-label for otitis, culture and sensitivity is essential as Pseudomonas (resistant to cefpodoxime) is a common ear pathogen.

Give the missed dose as soon as you remember, provided it is not close to the time for the next dose. If it is almost time for the next dose (within 4–6 hours), skip the missed dose and continue with the regular schedule. Do not double up doses. Continue the full prescribed course — stopping early, even if your dog appears better, risks relapse and contributes to antibiotic resistance development. If you miss multiple consecutive doses, contact your veterinarian as the treatment course may need to be restarted or extended.

For skin pyoderma, you should see reduction in redness, swelling, discharge, and itching within 5–7 days. For UTIs, urinary signs (dysuria, haematuria, frequency) should improve within 48–72 hours. If no improvement is seen after 5–7 days, the organism may be resistant — discontinue and perform culture/sensitivity testing before switching antibiotics. Never change antibiotics without culture data if possible. A recheck urinalysis and urine culture 5–7 days after completing a UTI course confirms eradication.

References

  1. Plumb DC. Plumb’s Veterinary Drug Handbook, 9th ed. Wiley-Blackwell; 2018.
  2. Simplicef (cefpodoxime proxetil) Prescribing Information. Zoetis Inc.; 2023.
  3. Papich MG. Antibiotic treatment of resistant infections in small animals. Vet Clin North Am Small Anim Pract. 2013;43(5):1091-1107.
  4. ISCAID Antimicrobial Use Guidelines for Urinary Tract Disease in Dogs and Cats. J Vet Intern Med. 2019;33(3):1236-1261.
  5. Mueller RS, et al. A review of topical therapy for skin infections with bacteria and yeast. Vet Dermatol. 2012;23(4):330-341.
  6. Beco L, et al. Suggested guidelines for using systemic antimicrobials in bacterial skin infections. Vet Rec. 2013;172(3):72.